首页> 外文期刊>Brain Tumor Pathology >MGMT promoter methylation and temozolomide response in choroid plexus carcinoma
【24h】

MGMT promoter methylation and temozolomide response in choroid plexus carcinoma

机译:MGMT启动子甲基化和替莫唑胺在脉络丛神经癌中的反应

获取原文
           

摘要

Choroid plexus carcinoma (CPC) is a malignant tumor with a strong tendency to spread along the cerebrospinal fluid pathway. There is no standardized chemotherapy protocol for this rare tumor. We report a 38-year-old man with CPC in the lateral ventricle with obstructive hydrocephalus. Because of the poor demarcation between thalamus and fornix, subtotal tumor resection was performed. Postoperative spine magnetic resonance (MR) image revealed whole spinal axis dissemination. After diagnosis of CPC, the patient was treated with whole ventricular and spine radiation concomitant with temozolomide chemotherapy, although the O 6-methylguanine-DNA methyltransferase (MGMT) promoter was found to be unmethylated. Although MR images revealed transient stable disease during adjuvant therapy, tumor progression was depicted after four cycles of temozolomide therapy. We discuss the ineffectiveness of adjuvant temozolomide therapy for CPC in connection with O 6-methylguanine-DNA methyltransferase promoter methylation.
机译:脉络丛神经癌(CPC)是一种恶性肿瘤,具有沿脑脊液途径扩散的强烈趋势。没有针对这种罕见肿瘤的标准化化疗方案。我们报告了一名38岁的男子,其CPC在梗阻性脑积水的侧脑室。由于丘脑和穹ni之间的分界不佳,因此进行了大体肿瘤切除术。术后脊柱磁共振(MR)图像显示整个脊柱轴扩散。诊断为CPC后,尽管发现O 6 -甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子未甲基化,但患者接受了全心室和脊柱放疗并接受替莫唑胺化疗。尽管MR图像显示辅助治疗期间出现短暂稳定的疾病,但在四个替莫唑胺治疗周期后显示了肿瘤进展。我们讨论了替莫唑胺辅助治疗CPC对O 6 -甲基鸟嘌呤-DNA甲基转移酶启动子甲基化的无效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号